Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Abnormal blood stem cells reprogram their environment

No. 15 | 07/04/2014 | by Koh

Blood arises from stem cells in the bone marrow; in patients with a myelodysplastic disorder (MDS), defective stem cells reprogram their neighbors in the marrow to create a “niche” that promotes their own survival. A recent report by scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in collaboration with colleagues from the University Medical Centre Mannheim, suggests that blocking the molecules involved in this process may lead to an effective therapy against this life-threatening blood disorder.


Patients suffering from a myelodysplastic disorder (MDS) exhibit highly unusual blood counts. Their hematopoietic stem cells – the source of blood – are defective, and they do not mature into functioning blood cells. As a result, MDS patients suffer from general physical weakness, internal bleeding and severe infections. About one third of MDS cases progress into acute myeloid leukemia, a type of blood cancer that is difficult to treat.

Several attempts have been made to transplant stem cells from MDS patients to mice, in hopes that the defective cells would multiply in the marrow and researchers could study their abnormal maturation. However, all these attempts have failed so far. "We had clues suggesting that the blood stem cells from MDS patients need specific conditions in the bone marrow in order to settle there," says Prof. Dr. Andreas Trumpp, who heads the Division of Stem Cells and Cancer at DKFZ and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), supported by the DKFZ and the Dietmar Hopp Foundation. “Now we have been able to prove this in a collaboration with Wolf-Karsten Hofmann and Daniel Nowak and their groups at the Department of Hematology and Oncology of the University Medical Centre Mannheim.”

In their recent work, the stem cell researchers turned to a trick: They transplanted the blood-forming cells of MDS patients along with so-called "niche cells" from the same person. Niche cells, or mesenchymal stromal cells, to use scientific terminology, settle predominantly in the bone marrow and produce a number of protein factors required for the survival of hematopoietic stem cells. The niche they form is a type of micro-environment in which stem cells flourish.

It turned out that only the niche cells taken from a patient, and not from healthy donors, led to a successful transplantation. A comparison of healthy niche cells with those taken from the patient revealed numerous genetic and molecular differences: a patient's cells produce different factors that promote the settling-in of transplanted MDS blood stem cells.

What causes this difference? Might it be caused by the abnormal blood stem cells themselves? Raising both cell types together in one culture dish, the scientists discovered that defective MDS blood stem cells are able to reprogram the niche cells of healthy donors; these subsequently begin producing excessive quantities of growth factors which, in turn, promote the survival of MDS stem cells.

"MDS blood stem cells and their niche apparently have an impact on each other, and this further aggravates the disorder in the formation of blood," says Dr. Hind Medyouf, first author of the publication. "This work provides the first indications that when the niche cells are reprogrammed by cells with the MDS defect, they produce protein factors that particularly promote the abnormal development of MDS stem cells, but fail to promote healthy blood stem cell development." Hence, the abnormal MDS blood stem cells and those of the niche form a functional unit that drives the disease further in a vicious cycle.

The new discovery of these interactions suggests a potential to use drugs or antibodies to inhibit growth factors that are excessively produced by the reprogrammed niche cells. Thus, the researchers hope to break the cycle and interfere early on in order to prevent MDS from progressing into leukemia.

Hind Medyouf, Maximilian Mossner, Johann-Christoph Jann, Florian Nolte, Simon Raffel, Carl Herrmann, Amelie Lier, Christian Eisen, Verena Nowak, Bettina Zens, Katja Müdder, Corinna Klein, Julia Obländer, Stephanie Fey, Jovita Vogler, Alice Fabarius, Eva Riedl, Henning Roehl, Alexander Kohlmann, Marita Staller, Claudia Haferlach, Nadine Müller, Thilo John, Uwe Platzbecker, Georgia Metzgeroth, Wolf-Karsten Hofmann, Andreas Trumpp and Daniel Nowak: Myelodysplastic cells in patients re-program mesenchymal stromal cells to establish a transplantable stem cell-niche disease unit. Cell Stem Cell 2014, DOI: 10.1016/j.stem.2014.02.014

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS